Publications by authors named "Andrew Strahs"

Claim this Profile
P
Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial.
Luca Sangiorgi, Ernest U Conrad, Fei Shih, Andrew Strahs, David S Feldman

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Robert J Pignolo, Mona Al Mukaddam, Geneviève Baujat, Matthew A Brown, Carmen De Cunto, Andrew R Strahs

BMC Med Res Methodol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.
William J Foster, Andrew L Strahs, Kent W Small, James M Roach

Drugs R D· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Robert J Pignolo, Edward C Hsiao, Mona Al Mukaddam, Geneviève Baujat, Staffan K Berglund, Andrew Strahs

J Bone Miner Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study.
Robert J Pignolo, Geneviève Baujat, Matthew A Brown, Carmen De Cunto, Edward C Hsiao, Andrew Strahs

Genet Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Robert J Pignolo, Geneviève Baujat, Edward C Hsiao, Richard Keen, Amy Wilson, Andrew L Strahs

J Bone Miner Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, Chih-Chao Yang, Mitsuharu Ueda, Andrew L Strahs

N Engl J Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs

N Engl J Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Corina N Oldenhuis, Walter J Loos, Brooke Esteves, Leni van Doorn, Monette M Cotreau, Andrew L Strahs

Clin Colorectal Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Monette M Cotreau, Nicholas M Siebers, James Miller, Andrew L Strahs, William Slichenmyer

Clin Pharmacol Drug Dev· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
Kathleen Moore, Jeffrey R Infante, Monette M Cotreau, Lindsey Wilson, Andrew L Strahs

Clin Pharmacol Drug Dev· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of food on the pharmacokinetics of tivozanib hydrochloride.
Monette M Cotreau, Lisa Massmanian, Andrew L Strahs, William Slichenmyer, Dennis L Vargo

Clin Pharmacol Drug Dev· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Robert J Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Andrew Strahs

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to T.G. Karrison.
Dmitry A Nosov, Andrew L Strahs

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Antonio C Wolff, Ann A Lazar, Igor Bondarenko, August M Garin, Stephen Brincat, Andrew Strahs

J Clin Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study.
Monette M Cotreau, Christine L Hale, Lindsey Jacobson, Claudine S Oelke, Andrew L Strahs

Clin Pharmacol Drug Dev· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Dmitry A Nosov, Brooke Esteves, Oleg N Lipatov, Alexei A Lyulko, A A Anischenko, Andrew Strahs

J Clin Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Christina M Coughlin, Daniel S Johnston, Andrew Strahs, Michael E Burczynski, Sarah Bacus

Breast Cancer Res Treat· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Arthur S Zbrozek, Gary Hudes, Donna Levy, Andrew Strahs, Anna Berkenblit

Pharmacoeconomics· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Robert A Figlin, Paul de Souza, David McDermott, Janice P Dutcher, Anna Berkenblit, Andrew Strahs

Cancer· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Georg Hess, Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef, Michael Crump, Andrew Strahs

J Clin Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Janice P Dutcher, Paul de Souza, David McDermott, Robert A Figlin, Anna Berkenblit, Andrew Strahs

Med Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy.
Monette M Cotreau, Vargheese M Chennathukuzhi, Heather A Harris, Lixin Han, Andrew J Dorner, Andrew L Strahs

Maturitas· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells.
Michael E Burczynski, Ron L Peterson, Natalie C Twine, Krystyna A Zuberek, Brendan J Brodeur, Andrew Strahs

J Mol Diagn· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects.
Caroline Trudeau, Monette M Cotreau, Lucille Stonis, Kevin H Dykstra, Judy L Oestreicher, Andrew Strahs

J Clin Pharmacol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis